These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36184017)

  • 1. Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs).
    Saraswat AL; Vartak R; Hegazy R; Patel A; Patel K
    Drug Discov Today; 2023 Jan; 28(1):103387. PubMed ID: 36184017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
    Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
    Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
    Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
    J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
    Zhu H; Wang J; Zhang Q; Pan X; Zhang J
    Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
    Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
    BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress of small molecules for targeted protein degradation: PROTACs and other technologies.
    Zhao HY; Xin M; Zhang SQ
    Drug Dev Res; 2023 Apr; 84(2):337-394. PubMed ID: 36606428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
    Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
    Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022.
    Tamatam R; Shin D
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approaches to targeted protein degradation technologies in drug discovery.
    Xue Y; Bolinger AA; Zhou J
    Expert Opin Drug Discov; 2023 Apr; 18(4):467-483. PubMed ID: 36895136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy.
    Moon Y; Jeon SI; Shim MK; Kim K
    Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural product-based PROteolysis TArgeting Chimeras (PROTACs).
    Liu M; Martyn AP; Quinn RJ
    Nat Prod Rep; 2022 Dec; 39(12):2292-2307. PubMed ID: 36196977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in AR-targeting chimeras: a case study of proteolysis-targeting chimeras from bench to bedside.
    Du W
    Future Med Chem; 2022 Oct; 14(20):1471-1489. PubMed ID: 36214138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROTACS: A technology with a gold rush-like atmosphere.
    Wang YW; Lan L; Wang M; Zhang JY; Gao YH; Shi L; Sun LP
    Eur J Med Chem; 2023 Feb; 247():115037. PubMed ID: 36566716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting androgen receptor degradation with PROTACs from bench to bedside.
    Jia X; Han X
    Biomed Pharmacother; 2023 Feb; 158():114112. PubMed ID: 36508999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Protein Degradation: Design Considerations for PROTAC Development.
    Tran NL; Leconte GA; Ferguson FM
    Curr Protoc; 2022 Dec; 2(12):e611. PubMed ID: 36469581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and bioactivity evaluation of self-assembled PROTACs based on multi-target kinase inhibitors.
    Si R; Zhu H; Wang J; Zhang Q; Li Y; Pan X; Zhang J
    Bioorg Chem; 2023 May; 134():106439. PubMed ID: 36842319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROTACs- a game-changing technology.
    Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
    Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
    [No Abstract]   [Full Text] [Related]  

  • 19. Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges.
    Edmondson SD; Yang B; Fallan C
    Bioorg Med Chem Lett; 2019 Jul; 29(13):1555-1564. PubMed ID: 31047748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROTACs technology for targeting non-oncoproteins: Advances and perspectives.
    Wang C; Zhang Y; Xing D; Zhang R
    Bioorg Chem; 2021 Sep; 114():105109. PubMed ID: 34175722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.